Speaking web
Responsible for allocating research funding
The Committee for Clinical Therapy Research decides which calls are to be made within the area. They also decide on which applications will be awarded grants. They have three review panels to help them examine and prioritise the applications submitted to the Swedish Research Council, before the Committee takes a decision. The review panels, which are appointed by the Committee, consist of international experts, statisticians and representatives of the Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU).
The research funded by the Committee must
- be clinical and conducted in national collaboration
- be based on the needs of health and medical care
- be expected to lead to benefits for patients and society within a relatively short period of time.
Following up and evaluating research in the area
The Committee follows up, evaluates, and produces strategies for the research area, for example through research overviews. In this work, the Committee is assisted by both national and international experts.
Strategic plan for the The Committee for Clinical Therapy Research 2020–2023
(pdf, 220.4 kB) (in Swedish)
The Swedish Research Council provides funding together with the Swedish Association of Local Authorities and Regions
The Swedish Research Council funds clinical therapy research in collaboration with the Swedish Association of Local Authorities and Regions. The Swedish Association of Local Authorities and Regions contributes half the funds that the Committee awards.
Composition of the Committee
The Committee for Clinical Therapy Research has thirteen members. The Government appoints the chair and six members, three of whom are proposed by the Swedish Research Council (following consultation with Vinnova). The other six members represent the county councils and regions and are appointed by the Swedish Association of Local Authorities and Regions, SALAR. Vinnova has a co-opted member of the committee. The term of office is three years and members can be reelected for a further three years.
The committee meets five times a year
Name | Title | Organisation |
|---|---|---|
Olle Stendahl (chair) | Professor Emeritus | Department of Clinical and Experimental Medicine, Linköping University |
Clas Ahlm | Professor Consultant, Norrland Director of Research and Education | Department of Clinical Microbiology, University Hospital Västerbotten County Council |
Boel Andersson Gäre | Professor
| Jönköping University Region Jönköping County |
Jan Andersson | Research Director | Stockholm County Council |
Anders Christensson | Professor Chief Medical Officer | Department of Clinical Sciences, Lund University Skåne University Hospital |
Lisa Ekselius | Professor Consultant | Department of Neuroscience, Uppsala University Hospital |
Lena Jonasson | Consultant Professor | Linköping University Hospital Linköping University |
Ann Hellström | Professor Consultant | Department of Neuroscience and Physiology, University of Gothenburg
|
Stefan Lohmander | Professor Emeritus | Department of Clinical Sciences Lund, Lund University |
Peter Lönnroth | Senior Advisor | Region Västra Götaland |
Beatrice Melin | Professor | Umeå University |
Petri Olivius | R&D manager | Sörmland County Council |
- In order to obtain a broad international perspective and a secure anchoring in society, the Committee has an advisory group to support the work. It contains representatives from
- The Public Health Agency of Sweden
- Forte, the Swedish Research Council for Health, Working Life and Welfare
- LIF, the Swedish Association of the Pharmaceutical Industry
- Swedish Medical Products Agency
- The Swedish Neurological Association
- The Swedish Rheumatism Association
- Rare Diseases Sweden
- Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)
- National Board of Health and Welfare
- The Swedish National Council on Medical Ethics
- SwedenBIO
- Swedish Medtech
- The Dental and Pharmaceutical Benefits Agency (TLV).
PublISHED ON 25 May 2018
UpDATED ON 12 February 2020